Asia Pacific IVF Market Research Report - By Reagents & Media, Instruments, Technology, End Users & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Size, Share, Trends & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 261
Pages: 145

APAC IVF Market Size (2023 to 2028)

The size of the Asia Pacific IVF Market is expected to be worth USD 1.21 billion by 2028 from USD 0.52 billion in 2023, growing at a CAGR of 18.4% from 2023 to 2028.

The increased awareness of various infertility treatments, the large population with rising infertility problems, the increase in the average age at first childbearing, and the declining fertility rate majorly drive the growth of the APAC IVF market. Owing to an increase in the incidence of infertility, hormonal insufficiency treatments, the trend of late pregnancy, advancement in technology related to IVF, and an increase in disposable income in the region, the in-vitro fertilization in the Asia-Pacific is anticipated to grow during the forecast period. It has been recorded that fertility rates are decreased in Asia-Pacific countries such as Japan, Singapore, India, Taiwan, South Korea, China, and Hong Kong. Lifestyle changes, including the preference for a stable life, increasing age at first birth, the shift from rural to urban societies, and declining marriage rates, among others, contribute to the decrease in the total fertility rate in these countries. According to the Australian Bureau of statistics 2015, In Australia, the average age of new mothers fell from 27.9 years in 2003 to 28.8 years in 2013. Several countries, such as Vietnam, Cambodia, and the Philippines, have fertility rates of 2 births per woman, which is lower than the average rate of 2.5 births per woman.

In older women over 40 years, the eggs produced by the reproductive system are not fully formed for fertilization or are produced in fewer numbers. This can lead to several risks of genetic disorders in the egg and complications in the pregnancy, such as miscarriage, pre-term babies, stillbirths, and other medical complications. Hence, an increase in the trend of late pregnancies among women is expected to drive the APAC IVF market's growth in the coming years. Furthermore, growth in IVF treatment knowledge, and low cost of IVF treatments with technological advancements, such as testicular sperm extraction techniques for overcoming the problems of spontaneous abortions, low fertility, and low embryonic quality, are in turn leading to high growth of fertility clinics in the Asia-Pacific region.

However, IVF treatment costs are subject to various reimbursement policies in different regions. Unfortunately, insurance companies generally do not cover the cost of infertility treatments. Infertility is not considered a severe health problem; therefore, it is not covered by general insurance. Thus, the high price of assisted reproduction techniques (ART) to treat infertility and the lack of awareness of treatment options are holding back the growth of this market. In addition, complications associated with IVF treatment, which might result in congenital disabilities or multiple pregnancies, are another major factor hampering the IVF market growth in this region. Also, low awareness levels regarding IVF amongst the population and high costs associated with IVF treatments are unaffordable by most of the population in some underdeveloped countries of this region, further obstructing the growth of the in-vitro fertilization market.

This research report on the Asia Pacific IVF Market has been segmented and sub-segmented into the following categories:

By Reagents and Media: 

  • Embryo Culture Media
  • Cryopreservation Media
  • Sperm Processing Media
  • Ovum Processing Media                   

By Instruments: 

  • Imaging Systems
  • Sperm Separation Systems
  • Ovum Aspiration Pumps
  • Incubators
  • Micromanipulator Systems
  • Cryosystems
  • Other Instruments (Gas Analyzers, Laser Systems, Accessories)                     

By Technology: 

  • Intra-Cytoplasmic Sperm Injection (ICSI)
  • Pre-Implantation Genetic Diagnosis (PGD)
  • Frozen Embryo Transfer/Replacement (FET/FER)
  • Other Technologies                             

By End Users: 

  • Fertility and Surgical Centers
  • Hospitals and Research Laboratories
  • Cryobanks                               

By Country: I

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

In 2021, APAC had a substantial share of the global market. The IVF services market in this region is majorly due to increasing medical tourism, a high population base, beneficial legal reviews related to IVF techniques, and an increase in the trend of delayed pregnancies among women led to continued growth prospects for the IVF services market in the Asia Pacific region. The rising incidence of infertility in this region can be attributed to lifestyle changes, poor diet, increased obesity and stress, increased pollution, lack of exercise, chronic diseases such as diabetes, and improper dietary habits. In addition, because of the senior population in this region, it has been researched that eggs produced are usually not fully formed for the fertilization process in older women above 40 years of age, which leads to not only infertility but also a risk of genetic disorders in the egg, which results in a decrease in the production of healthy eggs and an increased risk of miscarriage in young individuals. This increases the need for in-vitro fertilization services, leading to market growth.

In 2020, the Chinese market held the largest share of the APAC IVF market. Factors such as the rising infertility rate and fertility tourism have increased profitably, along with increased government regulations and disposable income, contributing to the growth of the IVF market in China. Also, due to economic development, foreign investment mentors are focusing more on entering economically developing countries and the changing regulatory landscape of those countries, leading to a rise in the number of key market players in China. Moreover, technological advancements, rising healthcare expenditures, increasing R&D activities in China, and increasing accessibility and availability of healthcare facilities leading to rising IVF success rates by most of the service providers present lucrative opportunities for major players operating in the fertility services market, which in turn leads to rapid IVF market growth in China.

The Indian market is expected to post the highest CAGR of 13.9% during the forecast period, owing to the availability of skilled professionals, increasing procedures per year, and technological advancements in the region. Other regions, such as Japan, Vietnam, Australia, and South Korea, are also expected to have reasonable growth rates in the years to come. The rapid growth of the senior population has been of great concern to the local government in the Asia-Pacific region. These regions focus on increasing fertility rates to balance neonatal and geriatric populations. Indonesia had a fertility rate of 2.3 and an aging population of around 5.2% of the total population in 2016. In addition to low-cost treatment, high-quality treatments, lesser strict fertility treatment laws also encourage fertility tourism in emerging Asian countries such as India, the Philippines, and Thailand. Many governments are providing better maternity benefits to increase the birth rate and improve medical facilities for IVF treatment. These potential drivers contribute to the mass adoption of IVF treatment in Asia-Pacific countries.


Companies playing a prominent role in the APAC IVF Market profiled in this report are CooperSurgical, Inc. (U.S.), Vitrolife AB (Sweden), Cook Medical, Inc. (U.S.), Irvine Scientific (U.S.), Thermo Fisher Scientific, Inc. (U.S.), EMD Serono, Inc. (U.S.), Genea Limited (Australia), ESCO Micro Pte. Limited (Singapore), IVFtech ApS (Denmark), and The Baker Company, Inc. (U.S.).

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample